Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages
Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages
复制标题
DOI：
10.1016/j.vaccine.2009.04.078
复制
发表时间：
2009-06-24
期刊：
影响因子：
5.5
通讯作者：
Iorio, A. M.
中科院分区：
文献类型：
--
作者：
Camilloni, B.;Neri, M.;Iorio, A. M.
本研究评估了 2003/04 冬季的 MF59 佐剂亚单位三价流感疫苗（A/莫斯科/10/99，H3N2；A/新喀里多尼亚/20/99，H1N1；B/香港/330/01）是否能提供针对 B/Victoria 和 B/Yamagata 样流感病毒株的错配和频繁共循环变种的保护。在中老年志愿者中测量了针对同源 B/Victoria 样疫苗株（B/Hong Kong/330/01）以及针对错配 B/Victoria 样疫苗株（B/Malaysia/2506/04）和 B/Yamagata 样疫苗株（B/Singapore/379/99 和 B/Shanghai/361/02）的血凝抑制（HI）抗体。免疫接种导致针对所有正在研究的乙型流感病毒株的 HI 抗体数量显着增加。然而，针对异源B/上海/361/02病毒的反应并未达到理想的血清保护值。发现 B/Victoria 样抗原的反应随年龄而下降，但 B/Yamagata 样菌株则不然。尽管还需要进一步研究，但我们的数据支持将 B/Victoria 和 B/Yamagata 谱系的乙型流感病毒纳入未来流感疫苗制剂中的建议。 (C) 2009 Elsevier Ltd. 保留所有权利。
This study evaluated whether MF59-adjuvanted subunit trivalent influenza vaccine for the 2003/04 winter season (A/Moscow/10/99, H3N2; A/New Caledonia/20/99, H1N1; B/Hong Kong/330/01) Would confer protection against mismatched and frequently co-circulating variants of influenza B/Victoria- and B/Yamagata-like virus strains. Haemagglutination inhibiting (HI) antibodies were measured in middle-aged and elderly volunteers against the homologous B/Victoria-like vaccine strain (B/Hong Kong/330/01) and against mismatched B/Victoria-like (B/Malaysia/2506/04) and B/Yamagata-like (B/Singapore/379/99 and B/Shanghai/361/02) strains. Immunization induced significant increases in the amounts of HI antibodies against all influenza B strains under investigation. However, the responses against the heterologous B/Shanghai/361/02 virus did not reach the desirable values of seroprotection. An age-dependent decline of the responses was found for B/Victoria-like antigens, but not for B/Yamagata-like strains. Although further studies are needed, our data support the recommendation of including influenza B viruses of the B/Victoria and B/Yamagata lineages in the future influenza vaccine preparations. (C) 2009 Elsevier Ltd. All rights reserved.